News

Merck & Co. (MRK) Announces that US FDA Approves ENFLONSIA™ For Preventing RSV Lower Respiratory Tract Disease
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that ...
NBC New York1mon
FDA approves Merck’s RSV shot for infants, ramping up competition ...
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 4:15 pm ...
US FDA approves Merck's RSV antibody for infants
The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the ...
WebMD1mon
FDA Approves Novavax COVID Vaccine With Restricted Use - WebMD
The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness ...
Business Wire1mon
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for ...
U.S. FDA Approves Merck’s ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering ... Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate.
NBC Chicago1mon
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - NBC Chicago
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...
NBC Bay Area1mon
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - NBC Bay Area
Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus. Skip to content. Main Navigation. Search. Search for: Local Weather ...
NBC Los Angeles1mon
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - NBC Los Angeles
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 1:15 pm ...
NBC DFW1mon
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - NBC 5 Dallas-Fort Worth
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...
NBC Washington1mon
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - NBC4 Washington
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...
NBC 6 South Florida1mon
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - NBC 6 South Florida
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 4:15 pm ...